Our research projects

Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.

Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.

Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.

Investigating a new method to improve the success of bone marrow transplants, using a different type of blood cells.

Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.

This research focuses on the development of novel drugs for the treatment of childhood brain tumours.

Osteosarcoma bone cancer affects teenagers, around half of whom die within 5-years of diagnosis. We think we can solve these problems by modifying immune cells called “gamma-delta T-cells”.

This work focuses on defining how a new oncoprotein (called CARM1) we have discovered in neuroblastoma cells helps the cancer cells to survive, grow and avoid death.

Craniopharyngioma, a brain tumour affecting children, is difficult to treat. Work within the laboratories of the investigators has identified potential drugs that could turn off tumour growth. These drugs will be tested in patients whose tumours have regrown in a clinical trial.